Akumin Inc. (AKU) Stock Analysis

Akumin Inc. (AKU) Healthcare & Pipeline Overview

Akumin Inc. delivers outpatient diagnostic imaging services in the U.S., offering radiology and oncology solutions to hospitals and health systems. With a network of 200 locations, the company provides MRI, CT, and other imaging modalities. Despite negative profitability, Akumin plays a crucial role in healthcare diagnostics.

What Is the Investment Thesis for AKU?

Akumin Inc. presents a complex investment case. While the company plays a vital role in providing outpatient diagnostic imaging services, its financial performance raises concerns. With a market capitalization of $26.3M and a negative P/E ratio of -0.17, the company's profitability is a significant challenge, further highlighted by a negative profit margin of -20.2%. The company's gross margin stands at 18.8%. Potential growth catalysts include expanding its network of imaging locations and increasing service offerings. However, the company must address its profitability issues to ensure long-term sustainability. Investors should closely monitor Akumin's ability to improve its financial performance and capitalize on growth opportunities in the diagnostic imaging market.

Based on FMP financials and quantitative analysis

AKU Key Highlights

Akumin operates approximately 200 owned and/or operated imaging locations across the United States.

• The company provides services to approximately 1,000 hospitals and health systems in 46 states.
• Akumin's market capitalization is $26.3M, reflecting its current market valuation.
• The company's P/E ratio is -0.17, indicating negative earnings.
• Akumin's profit margin is -20.2%, highlighting profitability challenges.

Who Are AKU's Competitors?

AKU is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are AKU's Key Strengths?

Extensive network of imaging centers.

• Established relationships with hospitals and health systems.
• Comprehensive range of diagnostic imaging services.
• Presence in multiple states across the United States.

What Are AKU's Weaknesses?

Negative profit margin.

• High debt levels.
• Dependence on reimbursement rates.
• Competition from larger imaging providers.

What Could Drive AKU Stock Higher?

Expansion of imaging center network through acquisitions and new site development.

• Implementation of new technologies to improve diagnostic accuracy and efficiency.
• Potential partnerships with healthcare providers to expand referral network.
• Focus on oncology services to capitalize on growing demand for cancer diagnostics and treatment.

What Are the Key Risks for AKU?

Financial-distress signal — its Altman Z-Score of -1.00 sits in the distress zone (elevated bankruptcy risk).

• Changes in reimbursement policies affecting revenue and profitability.
• Increased competition from other imaging providers.
• Economic downturn affecting healthcare spending.
• Technological obsolescence requiring significant capital investment.
• Integration risks associated with acquisitions.

What Are the Growth Opportunities for AKU?

• Expansion of Service Offerings: Akumin can expand its service offerings to include more specialized diagnostic procedures and interventional radiology services. This would allow the company to attract a broader range of patients and increase revenue per location. The market for specialized diagnostic services is growing, driven by advancements in medical technology and increasing demand for personalized medicine. Timeline: 1-2 years. Market Size: $10 billion annually.
• Strategic Acquisitions: Akumin can pursue strategic acquisitions of smaller imaging centers and radiology practices to expand its geographic footprint and market share. This would allow the company to enter new markets and consolidate its position in existing markets. The market for imaging center acquisitions is active, with numerous opportunities available. Timeline: Ongoing. Market Size: $5 billion annually.
• Technological Upgrades: Investing in advanced imaging technologies, such as AI-powered diagnostic tools and high-resolution imaging systems, can improve the accuracy and efficiency of Akumin's services. This would allow the company to attract more patients and improve patient outcomes. The market for advanced imaging technologies is growing rapidly. Timeline: 1-3 years. Market Size: $3 billion annually.
• Partnerships with Healthcare Providers: Akumin can form strategic partnerships with hospitals, physician groups, and other healthcare providers to expand its referral network and increase patient volume. This would allow the company to access a larger pool of patients and integrate its services into the broader healthcare ecosystem. Timeline: Ongoing. Market Size: $2 billion annually.
• Focus on Oncology Services: Akumin can focus on expanding its oncology services, such as PET/CT imaging and radiation therapy, to capitalize on the growing demand for cancer diagnostics and treatment. This would allow the company to tap into a high-growth market segment and improve its profitability. The market for oncology services is growing rapidly. Timeline: 2-3 years. Market Size: $7 billion annually.

What Are AKU's Competitive Advantages?

• Extensive network of approximately 200 imaging locations.
• Relationships with approximately 1,000 hospitals and health systems.
• Comprehensive suite of diagnostic imaging services.
• Established presence in 46 states across the United States.

What Does AKU Do?

Akumin Inc., founded in 2015 and headquartered in Plantation, Florida, is a prominent provider of outpatient diagnostic imaging services in the United States. The company operates through two primary segments: Radiology and Oncology. Akumin offers a comprehensive suite of medical imaging services, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, and various other diagnostic and interventional radiology procedures. These services are delivered through a network of approximately 200 owned and/or operated imaging locations. Akumin's services cater to a broad spectrum of healthcare needs, supporting the diagnostic and treatment pathways for numerous medical conditions. The company partners with approximately 1,000 hospitals and health systems across 46 states, providing them with outpatient radiology and oncology services and solutions. This extensive network allows Akumin to reach a significant patient population and contribute to the efficiency and effectiveness of healthcare delivery. The company's focus on outpatient services aims to provide convenient and cost-effective access to essential diagnostic imaging, reducing the burden on hospital resources and improving patient outcomes. Akumin's commitment to innovation and quality in diagnostic imaging has positioned it as a key player in the evolving healthcare landscape.

What Products and Services Does AKU Offer?

• Provides outpatient diagnostic imaging services.
• Offers magnetic resonance imaging (MRI) services.
• Performs computed tomography (CT) scans.
• Conducts positron emission tomography (PET) scans.
• Offers nuclear medicine services.
• Provides mammography and ultrasound services.
• Delivers digital radiography and fluoroscopy procedures.
• Offers interventional radiology procedures.

How Does AKU Make Money?

• Generates revenue by providing diagnostic imaging services to patients.
• Contracts with hospitals and health systems to provide outpatient radiology and oncology solutions.
• Operates a network of owned and/or operated imaging locations.
• Focuses on outpatient services to provide convenient and cost-effective access to diagnostic imaging.

What Industry Does AKU Operate In?

The medical diagnostics and research industry is experiencing growth driven by technological advancements, an aging population, and increasing prevalence of chronic diseases. Companies like Akumin play a crucial role in providing essential diagnostic imaging services. The industry is competitive, with players like ABDXF (Abdos Healthcare), AWH (American WholeHealth), CNTG (Centogene), DMTKQ (DMC Global Inc.), and LMDX (Lantheus Holdings) vying for market share. Market trends include a shift towards outpatient services, increasing demand for advanced imaging modalities, and the integration of AI and machine learning to improve diagnostic accuracy and efficiency.

Who Are AKU's Key Customers?

• Hospitals and health systems across the United States.
• Physician groups and medical practices.
• Patients requiring diagnostic imaging services.
• Oncology centers and cancer treatment facilities.

How Akumin Inc. Is Valued

Akumin Inc. carries a market capitalization of $26.3M, placing it in the micro-cap category.

Company Profile

Akumin Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Plantation, US. The company is led by CEO Riadh Zine-El-Abidine. AKU has traded publicly since 2020.

Key Financial Metrics

Return on assets is -8.6%, showing how much profit it generates from its asset base. Its free cash flow yield is 78.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.14 indicates the company holds enough short-term assets to cover its near-term obligations.

Akumin Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -1.00 places it in the distress zone, a signal of elevated financial risk.

The most recent 8 insider filings for Akumin Inc. break down as 0 sales and 8 purchases. On net that is roughly 1.0M shares acquired (about $0) — insiders putting money in tends to read as conviction.

AKU Financials

AKU Latest News

Akumin Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources